ProShare Advisors
IPSC icon

ProShare Advisors’s Century Therapeutics IPSC Stock Holding History

ProShare Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,131
Closed -$4.82K – 2129
2025
Q1 		$4.82K Sell
10,131
-3,049
-23% -$2.29K ﹤0.01% 2075
2024
Q4 		$13.3K Buy
+13,180
New +$17.9K ﹤0.01% 2262
2022
Q1 		– Sell
-10,273
Closed -$163K – 2251
2021
Q4 		$163K Buy
+10,273
New +$193K ﹤0.01% 2098

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's IPSC Position: Q2 2025 in Review

ProShare Advisors sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 10,131 shares — an estimated $4.82K sold.

ProShare Advisors first reported a position in IPSC in Q4 2021 and held it in 3 quarters. The position peaked at $163K in Q4 2021. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • ProShare Advisors reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,131 Century Therapeutics shares in Q2 2025, an estimated $4.82K.
  • ProShare Advisors first reported a position in Century Therapeutics in Q4 2021 and held it in 3 quarters.
  • ProShare Advisors's Century Therapeutics position peaked at $163K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.